Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD)

Kidney International

Volumn 67, Issue 6, 2005, Pages 2295-2304

  Moe, Sharon M ^a   Reslerova, Martina ^b   Ketteler, Markus ^b   O'Neill, Kalisha ^b   Duan, Danxia ^b   Koczman, Jacob ^b   Westenfeld, Ralf ^b   Jahnen Dechent, Willi ^b   Chen, Neal X ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

CKD; Dialysis; Fetuin A; Matrix gla protein; Osteoprotegerin; Vascular calcification

Indexed keywords

FETUIN; OSTEOCALCIN; OSTEOPROTEGERIN; ALPHA2HS GLYCOPROTEIN; CALCIUM BINDING PROTEIN; CELL RECEPTOR; GLYCOPROTEIN; MATRIX GLA PROTEIN; PLASMA PROTEIN; SCLEROPROTEIN; TNFRSF11B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; BLOOD VESSEL CALCIFICATION; CHRONIC KIDNEY DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EX VIVO STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MINERALIZATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BLOOD; CALCINOSIS; CATTLE; CELL CULTURE; CHRONIC DISEASE; CYTOLOGY; KIDNEY DISEASE; PHYSIOLOGY; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

ANIMALS; BLOOD PROTEINS; CALCINOSIS; CALCIUM-BINDING PROTEINS; CATTLE; CELLS, CULTURED; CHRONIC DISEASE; EXTRACELLULAR MATRIX PROTEINS; GLYCOPROTEINS; HUMANS; KIDNEY DISEASES; MUSCLE, SMOOTH, VASCULAR; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; VASCULAR DISEASES;

EID: 20844432154     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00333.x     Document Type: Article

References (51)

1. FOLEY RN, PARFREY PS, SARNAK MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:8112-8119,1998
2. CHEUNG AK, SARNAK MJ, YAN G, et al Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58:353-362, 2000
3. BLOCK GA, KLASSEN PS, LAZARUS JM, et al Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208-2218, 2004
4. MOE SM, CHEN NX: Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 95:560-567, 2004
5. BRAUN J, OLDENDORF M, MOSHAGE W, et al Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27:394-401, 1996
6. SCHWARZ U, BUZELLO M, RITZ E, et al: Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15:218-223, 2000
7. GOODMAN WG, GOLDIN J, KUIZON BD, et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483, 2000
8. BLACHER J, GUERIN AP, PANNIER B, et al: Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38:938-942, 2001
9. LONDON GM, GUERIN AP, MARCHAIS SJ, et al: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18:1731-1740, 2003
10. MOE SM, O'NEILL KD, RESELEROVA M, et al: Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transplant 19:2387-2393, 2004
11. HUJAIRI NM, AFZALI B, GOLDSMITH D J: Cardiac calcification in renal patients: What we do and don't know. Am J Kidney Dis 43:234-243, 2004
12. JAHNEN-DECHENT W, SCHAFER C, HEISS A, et al: Systemic inhibition of spontaneous calcification by the serum protein alpha 2-HS glycoprotein/fetuin. Z Kardiol 90 (Suppl 3):47-56, 2001
13. BUCAY N, SAROSI I, DUNSTAN CR, et al: osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260-1268, 1998
14. Luo G, DUCY P, McKEE MD, et al: Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386:78-81, 1997
15. SCHAFER C, HEISS A, SCHWARZ A, et al: The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112:357-366, 2003
16. MOE SM, O'NEILL KD, DUAN D, et al: Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins Kidney Int 61:638-647, 2002
17. MOE SM, O'NEILL KD, FINEBERG N, et al: Assessment of vascular calcification in ESRD patients using spiral CT. Nephrol Dial Transplant 18:1152-1158, 2003
18. KETTELER M, BONGARTZ P, WESTENFELD R, et al: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. Lancet 361:827-833, 2003
19. CHEN NX, O'NEILL KD, DUAN D, et al: Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 62:1724-1731, 2002
20. MOE SM, DUAN D, DOEHLE BP, et al: Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 63:1003-1011, 2003
21. MALYANKAR UM, SCATENA M, SUCHLAND KL, et al: Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 275:20959-20962, 2000
22. WALLIN R, CAIN D, HUTSON SM, et al: Modulation of the binding of matrix G1a protein (MGP) to bone morphogenetic protein-2 (BMP-2). Thromb Haemost 84:1039-1044, 2000
23. RAGGI P, BOULAY A, CHASAN-TABER S, et al: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Colt Cardiol 39:695-701, 2002
24. KETTELER M, WANNER C, METZGER T, et al: Deficiencies of calcium-regulatory proteins in dialysis patients: A novel concept of cardio-vascular calcification in uremia. Kidney Int (Suppl):S84-S87, 2003
25. HEISS A, DuCHESNE A, DENECKE B, et al: Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem 278:13333-13341, 2003
26. SCHINKE T, AMENDT C, TRINDL A, et al: The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem 271:20789-20796, 1996
27. WANG H, ZHANG M, BIANCHI M, et al: Fetuin (alpha2-HS-glycoprotein) opsonizes cationic macrophagedeactivating molecules. Proc Natl Acad Sci USA 95:14429-14434, 1998
28. PRICE PA, BUCKLEY JR, WILLIAMSON MK: The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats.J Nutr 131:2910-2915, 2001
29. PRICE PA, CAPUTO JM, WILLIAMSON MK: Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix G1a protein: Biochemical evidence for the cancellous bone-remodeling compartment. J Bone Miner Res 17:1171-1179, 2002
30. PRICE PA, WILLIAMSON MK, NGUYEN TM, et al: Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat. J Biol Chem 279:1594-1600, 2004
31. PRICE PA, FAUS SA, WILLIAMSON MK: Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vase Biol 21:817-824, 2001
32. JONO S, IKARI Y, SHIOI A, et al Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106:1192-1194, 2002
33. NITTA K, AKIBA T, UCHIDA K, et al The progression of vascular calcification and serum osteoprotegerin levels in patients on longterm hemodialysis. Am J Kidney Dis 42:303-309, 2003
34. NITTA K, AKIBA T, UCHIDA K, et al. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant 19:1886-1889, 2004
35. KAZAMA JJ, SHIGEMATSU T, YANO K, et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 39:525-532, 2002
36. CHEN N, MOE S: Vascular calcification in chronic kidney disease. Semin Nephrol 24:61-68, 2004
37. MIN H, MORONY S, SAROSI I, et al: Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192:463-474, 2000
38. BEKKER PJ, HOLLOWAY D, NAKANISHI A, et al: The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16:348-360, 2001
39. CAPPARELLI C, MORONY S, WARMINGTON K, et al: Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): A pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res 18:852-858, 2003
40. LONDON GM, MARTY C, MARCHAIS SJ, et al: Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15:1943-1951, 2004
41. COEN G, BALLANT: P, BALDUCCI A, et al: Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 17:233-238, 2002
42. KURZ P, MONIER-FAUGERE MC, BOGNAR B, et al Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 46:855-861, 1994
43. HAAS M, LEKO-MOHR Z, ROSCHGER P, et al Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis 39:580-586, 2002
44. SCHURGERS LJ, AEBERT H, VERMEER C, et al Oral anticoagulant treatment: Friend or foe in cardiovascular disease? Blood 2004 (in press)
45. AHMED S, O'NEILL KD, HOOD AF, et al Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis 37:1267-1276, 2001
46. BOSTROM K, TSAO D, SHEN S, et al: Matrix gla protein modulates differentiation induced by bone morphogenetic protein-2 in c3h10t1/2 cells. J Biol Chem 276:14044-14052, 2001
47. SHANAHAN CM, GARY NR, METCALFE JC, et al: High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 93:2393-2402, 1994
48. SPRONK HM, SOUTE BA, SCHURGERS LJ, et al: Matrix G1a protein accumulates at the border of regions of calcification and normal tissue in the media of the arterial vessel wall. Biochem Biophys Res Commun 289:485-490, 2001
49. ZEBBOUDJ AF, SHIN V, BOSTROM K: Matrix GLA protein and BMP-2 regulate osteoinduction in calcifying vascular cells. J Cell Biochem 90:756-765, 2003
50. MORI K, SHIOI A, JONO S, et al: Expression of matrix G1a protein (MGP) in an in vitro model of vascular calcification. FEBS Lett 433:19-22, 1998
51. JONO S, IKARI Y, VERMEER C, et al: Matrix G1a protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Thromb Haemost 91:790-794, 2004